End-of-day quote
Shanghai S.E.
23:00:00 20/06/2024 BST
|
5-day change
|
1st Jan Change
|
102.5
CNY
|
+0.23%
|
|
-2.31%
|
-17.70%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
7,455
|
24,524
|
17,502
|
17,008
|
13,998
|
-
|
-
|
Enterprise Value (EV)
1 |
7,455
|
24,524
|
17,502
|
17,008
|
13,998
|
13,998
|
13,998
|
P/E ratio
|
134
x
|
480
x
|
182
x
|
148
x
|
86.9
x
|
63.7
x
|
46.6
x
|
Yield
|
-
|
0.2%
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
97.4
x
|
-
|
45.9
x
|
27.3
x
|
20.2
x
|
15.2
x
|
EV / Revenue
|
-
|
97.4
x
|
-
|
45.9
x
|
27.3
x
|
20.2
x
|
15.2
x
|
EV / EBITDA
|
-
|
-
|
-
|
128
x
|
74.5
x
|
51.5
x
|
35.8
x
|
EV / FCF
|
-
|
5,714,426,544
x
|
-
|
1,323,958,996
x
|
-
|
-
|
-
|
FCF Yield
|
-
|
0%
|
-
|
0%
|
-
|
-
|
-
|
Price to Book
|
-
|
24.8
x
|
-
|
14.2
x
|
11.2
x
|
10.6
x
|
9.71
x
|
Nbr of stocks (in thousands)
|
134,400
|
135,014
|
135,673
|
136,579
|
136,579
|
-
|
-
|
Reference price
2 |
55.47
|
181.6
|
129.0
|
124.5
|
102.5
|
102.5
|
102.5
|
Announcement Date
|
29/01/21
|
21/02/22
|
27/02/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
251.8
|
-
|
370.6
|
513
|
692
|
923
|
EBITDA
1 |
-
|
-
|
-
|
132.5
|
188
|
272
|
391
|
EBIT
1 |
-
|
52.61
|
-
|
120.8
|
179
|
247
|
343
|
Operating Margin
|
-
|
20.89%
|
-
|
32.6%
|
34.89%
|
35.69%
|
37.16%
|
Earnings before Tax (EBT)
1 |
-
|
49.76
|
-
|
120
|
178
|
246
|
342
|
Net income
1 |
56.02
|
51.2
|
95.74
|
115.2
|
161
|
220
|
300
|
Net margin
|
-
|
20.33%
|
-
|
31.08%
|
31.38%
|
31.79%
|
32.5%
|
EPS
2 |
0.4143
|
0.3786
|
0.7100
|
0.8400
|
1.180
|
1.610
|
2.200
|
Free Cash Flow
|
-
|
4.292
|
-
|
12.85
|
-
|
-
|
-
|
FCF margin
|
-
|
1.7%
|
-
|
3.47%
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
9.69%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
8.38%
|
-
|
11.15%
|
-
|
-
|
-
|
Dividend per Share
|
-
|
0.3571
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
29/01/21
|
21/02/22
|
27/02/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
4.29
|
-
|
12.8
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
5.65%
|
-
|
10.1%
|
12.9%
|
16.6%
|
20.8%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
9.22%
|
11.7%
|
13.1%
|
15%
|
Assets
1 |
-
|
-
|
-
|
1,250
|
1,376
|
1,679
|
2,000
|
Book Value Per Share
2 |
-
|
7.330
|
-
|
8.750
|
9.130
|
9.710
|
10.60
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
72.2
|
-
|
128
|
250
|
250
|
250
|
Capex / Sales
|
-
|
28.67%
|
-
|
34.62%
|
48.73%
|
36.13%
|
27.09%
|
Announcement Date
|
29/01/21
|
21/02/22
|
27/02/23
|
28/02/24
|
-
|
-
|
-
|
Last Close Price
102.5
CNY Average target price
138
CNY Spread / Average Target +34.65% Consensus |
1st Jan change
|
Capi.
|
---|
| -17.70% | 1.93B | | +14.42% | 131B | | -7.56% | 11.06B | | -15.80% | 7.33B | | +42.18% | 5.69B | | -20.14% | 4.83B | | +8.58% | 3.45B | | -19.51% | 2.47B | | -19.46% | 1.79B | | -34.15% | 1.52B |
Medical Devices & Implants
|